Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.
Clinical genitourinary cancer. 2018 Jul 20 [Epub ahead of print]
Roberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, Giampaolo Tortora
Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy. Electronic address: ., Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy., Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.